Phase I/II, Open-Label, Dose Escalation Study of the Safety, Pharmacokinetics and Pharmacodynamics of NV1205 in Pediatric Male Subjects With Childhood Cerebral Adrenoleukodystrophy (CCALD)

Trial Profile

Phase I/II, Open-Label, Dose Escalation Study of the Safety, Pharmacokinetics and Pharmacodynamics of NV1205 in Pediatric Male Subjects With Childhood Cerebral Adrenoleukodystrophy (CCALD)

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 01 Aug 2018

At a glance

  • Drugs Sobetirome (Primary)
  • Indications Adrenoleucodystrophy
  • Focus Adverse reactions
  • Sponsors NeuroVia
  • Most Recent Events

    • 26 Jul 2018 Planned initiation date (estimated date for recruitment of the first subject) changed from 1 May 2018 to 1 Aug 2018.
    • 25 Jul 2018 According to a NeuroVia media release, this study has been initiated in Australia, Chile and the United Kingdom.
    • 05 Jun 2018 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top